Description: Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of non?alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188 (N,N-Dimethyltryptamine), a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
Home Page: algernonpharmaceuticals.com
601 West Broadway
Vancouver,
BC
V5Z 4C2
Canada
Phone:
604 398 4175
Officers
| Name | Title |
|---|---|
| Mr. Christopher J. Moreau | CEO & Director |
| Mr. James F. Kinley C.A., CPA | Chief Financial Officer |
| Dr. Christopher Bryan Ph.D. | Vice President of Research & Operations |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9081 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | August |
| Full Time Employees: | 0 |